# Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

> **NCT02461888** · PHASE2 · COMPLETED · sponsor: **University of Leeds** · enrollment: 112 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02461888
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2022-04
- **Final completion:** 2025-01-19
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461888, "Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02461888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*